Privia Health Group, Inc. research snapshot
PRVA AI stock analysis reads Privia Health Group as a high-quality physician enablement platform with strong revenue growth, improving adjusted profitability, and a stock price that still carries a premium multiple. The analysis is not a certain price prediction. At the August 3, 2026 data cutoff, PRVA traded near $24.04, down from a July 16 intraday high of $28.82, with a market capitalization of about $3.03 billion. The stock sells for roughly 141x trailing GAAP earnings and about 25x the 2026 adjusted EPS consensus of $0.95, and the next major test is the August 6, 2026 second quarter earnings report. This is informational research and not investment advice.
Current price
$24.04
Market cap
$3.03 billion
AI score
56 / 100
Rating
Quality physician enablement grower at a premium valuation
Trend status
Pullback within a 2026 uptrend, testing the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Privia Health enables independent physician groups to run their practices through technology, management services, population health tools, and value-based care contracts. TTM revenue grew about 24.7% to roughly $2.25 billion. | Medium-high |
| Moat | The moat comes from physician network stickiness, the single-TIN medical group structure, integrated technology, and scale in value-based care contracting. Barriers are moderate and are still being proven through a full payment cycle. | Medium |
| Management | CEO Parth Mehrotra leads the company, CFO David Mountcastle manages a balance sheet with roughly $410 million in net cash, and guidance has been delivered consistently. Insiders own about 5.7%, but there were zero insider buys and about $18.7 million in insider sales over the past 12 months. | Medium |
| Financial trend | TTM revenue reached about $2.25 billion, up 24.7%, with TTM net income of about $21.8 million and TTM operating cash flow of about $138 million. GAAP net margin is thin at about 1%, while Q1 2026 adjusted EBITDA grew 36% year over year. | Medium-high |
| Valuation | At about 141x trailing GAAP earnings, 74x forward GAAP earnings, 1.35x sales, and 22x free cash flow, the market prices in strong continued growth. The 2026 adjusted EPS consensus of $0.95 implies a forward adjusted multiple near 25x. | Medium |
| Technical trend | PRVA rallied from about $21.40 in early June to an intraday high of $28.82 on July 16, then corrected to the $23.40 to $23.70 zone where the 200-day moving average sits. Momentum has weakened with RSI near 35. | Medium-high |
| Risk level | Key risks are the high multiple, thin GAAP margins, stock-based compensation dilution, consistent insider selling, health plan and policy dependence, competition from other enablement platforms, and first quarter working capital swings. | Medium-high |
| AI confidence | Confidence is higher for revenue, market cap math, guidance, and analyst consensus. It is lower for the sustainability of attributed lives growth, margin trajectory, and competitive response. | Medium |
| Investment certainty | Low-to-medium. Fundamentals are solid, but the stock must re-rate from a rich multiple, and the August 6 earnings report is the near-term hinge. | Low-to-medium |
PRVA AI stock forecast
The PRVA AI stock forecast uses scenario ranges around the $24.04 reference price and the 2026 adjusted EPS consensus of $0.95. It does not claim that AI can predict a specific future price. The ranges come from a three-year financial_rigor.py sensitivity that compounds adjusted EPS at different growth rates and applies different terminal multiples. The bullish case assumes faster growth and a maintained premium. The base case assumes steady growth with a moderate multiple. The bearish case assumes growth slows and the multiple compresses.
$40 to $46
More likely if PRVA sustains high-teens revenue growth, raises full-year guidance on August 6, expands adjusted EBITDA margins toward the $155 million end of guidance, and holds a forward adjusted multiple near 30x as analysts keep upgrading.
$28 to $33
More likely if revenue grows around 14% toward the $2.42 billion consensus, adjusted EBITDA lands near the middle of the $145 to $155 million guidance, and the stock holds a forward adjusted multiple in the low-to-mid 20s.
$16 to $20
More likely if growth slows, the August 6 report misses or guidance disappoints, physician retention weakens, healthcare policy hurts value-based care economics, or the stock de-rates toward a mid-to-high teens multiple typical of slower growth services firms.
PRVA AI technical analysis
PRVA AI technical analysis starts from the $24.04 reference price captured intraday on August 3, 2026, with the prior close at $23.67 on July 31. The stock sits below its 50-day moving average of $24.41 and just above its 200-day moving average of $23.65, with RSI near 35. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting, especially ahead of the August 6 earnings report.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $24.04 | Intraday quote captured August 3, 2026. The July 31 close of $23.67 is the last completed session. |
| Near support | $23.40 to $23.70 | The 200-day moving average near $23.65 and the late-July low around $23.41. This is the immediate test for the current pullback. |
| Secondary support | $22.90 to $23.10 | The early-to-mid June consolidation area. A close below this zone would point to a deeper correction. |
| Next support | $21.30 to $21.50 | The June 8 swing low near $21.36. Holding this area keeps the 2026 uptrend structure intact. |
| Near resistance | $24.90 to $25.60 | The late-July breakdown area where sellers stepped in on July 22-24. A reclaim would be the first positive sign. |
| Secondary resistance | $27.00 to $28.82 | The July 13-16 price zone and the 52-week intraday high of $28.82. A return to this area likely needs a fundamental catalyst. |
| 52-week range | $18.77 to $28.82 | Per StockAnalysis as of August 2026. PRVA has still gained about 20.8% over the past 52 weeks despite the July correction. |
| Momentum | Weakening, RSI near 35 | The stock broke below its 50-day moving average. RSI of about 34.7 signals a near-term oversold condition rather than a confirmed trend reversal. |
| Volume | About 1.13 million shares average (20-day) | The July pullback came with above-average volume on several days. Watch whether the next move is confirmed by rising volume. |
| Volatility | Beta 0.83 to 0.84, below market | PRVA has lower volatility than the overall market, which may appeal to risk-aware growth investors. |
| Invalidation | Close below $23.40, then $22.90 | A daily close below the 200-day area weakens the pullback trade. Breaking the June base would question the 2026 uptrend. |
PRVA AI trading strategy
The PRVA AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels, and it treats the August 6 earnings report as the key risk event.
Wait for a close back above the $24.90 to $25.60 resistance zone on above-average volume to signal that the pullback has stabilized, before treating the next leg up as confirmed.
A failed reclaim, or a close below the $23.40 to $23.70 support area, should reduce confidence in the setup.
If PRVA holds the $23.40 to $23.70 support near the 200-day moving average, monitor the August 6 earnings and guidance before considering an entry, because the report can gap the stock through either side of the range.
Do not treat an oversold RSI as a buy signal by itself. The roughly 141x trailing GAAP multiple leaves little room for a miss.
Track the August 6, 2026 second quarter report, full-year 2026 guidance, revenue growth, adjusted EBITDA margin, attributed lives growth, provider additions, and insider trading activity.
Lower the rating if guidance disappoints, adjusted EBITDA misses, attributed lives growth decelerates, or insider selling continues without any insider buying.
Investment research summary
Privia Health provides technology, analytics, and network services that let independent physicians and groups run better practices, manage population health, and participate in value-based care contracts. Clients pay for revenue growth, cost control, and relief from administrative burden.
The moat is physician network retention, the single-TIN medical group structure, integrated technology, and scaled value-based care infrastructure. These create switching costs, but they are not impenetrable and competitors keep investing in the same model.
The thesis fails if revenue growth slows below guidance, adjusted EBITDA margins do not expand, physician groups leave the network, health plans renegotiate payment terms, healthcare policy shifts against value-based care, or the stock de-rates from its rich multiple.
CEO Parth Mehrotra and CFO David Mountcastle have run the company conservatively with a large net cash position and have delivered consistent guidance. The concern is zero insider buying and about $18.7 million of insider selling over the past 12 months.
The shift toward value-based care, physician practice consolidation, and healthcare technology is a multi-year tailwind. Privia is one of the largest physician enablement companies with a presence in 24 states plus DC, more than 5,500 providers, and about 1.6 million attributed lives.
At about 141x trailing GAAP earnings, 25x forward adjusted earnings, and 1.35x sales, the stock price prices in years of successful execution. The roughly $410 million net cash position and 22x free cash flow give some support, but there is no deep margin of safety.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PRVA price | $24.04 intraday on August 3, 2026; prior close $23.67 on July 31 | Google Finance and StockAnalysis | August 3, 2026 |
| Market capitalization | $3.03 billion, verified as $24.04 x 126.01M shares with financial_rigor.py (0.02% deviation) | StockAnalysis and financial_rigor.py | August 3, 2026 |
| TTM revenue | About $2.25 billion through Q1 2026, up 24.7% year over year | StockAnalysis financials | August 3, 2026 |
| TTM net income | About $21.8 million, about 1% net margin | StockAnalysis statistics | August 3, 2026 |
| TTM GAAP EPS | $0.17 | Google Finance and StockAnalysis | August 3, 2026 |
| FY2026 revenue guidance | $2.35 billion to $2.45 billion, reiterated May 7, 2026 | Privia Health Q1 2026 press release | May 7, 2026 |
| FY2026 adjusted EBITDA guidance | $145 million to $155 million, reiterated May 7, 2026 | Privia Health Q1 2026 press release | May 7, 2026 |
| Q1 2026 (March) results | Revenue $603.8 million up 25.8%; adjusted EBITDA $36.7 million up 36.3%; practice collections $914.8 million up 14.6% | Privia Health Q1 2026 press release | May 7, 2026 |
| Valuation math | 141.4x TTM PE, 1.35x PS, 4.01x PB, 21.85x P/FCF, forward adjusted PE about 25x from financial_rigor.py | financial_rigor.py and StockAnalysis | August 3, 2026 |
| Analyst consensus | Strong Buy from about 20 analysts, average target $31.89, range $24 to $40 | StockAnalysis forecast / S&P Global | August 3, 2026 |
| Insider trading | 0 insider buys, 4 insider sellers, about $18.7 million of insider selling in the past 12 months | MarketBeat insider trading | August 3, 2026 |
| 52-week range | $18.77 to $28.82 (Google Finance shows $18.92 to $28.82) | StockAnalysis and Google Finance | August 3, 2026 |
This PRVA AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
